Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Weekly News
  • IR Room
  • RESEARCH
    • Semiconductors
  • Disclosures
    • Semiconductors
    • Energy
    • Bio & Healthcare
    • Defense
    • Shipbuilding
    • Automotive
  • Toggle search form
  • [Disclosure] Samsung Biologics (207940) – Change in Profit and Loss Structure Exceeding 30% (15% for Large Corporations) / 2024-01-24 Disclosures
  • [Disclosure] Jusung Engineering (036930) – New Facility Investment / 2025-06-09 Semiconductors
  • [Disclosure] Hyundai Motor (005380) – Decision on Disposal of Treasury Stock / 2024-08-22 Disclosures
  • [Disclosure] PSK Holdings (031980) – Investor Relations (IR) Host / 2024-11-08 Semiconductors
  • [Disclosure] Jeju Semiconductor (080220) – Change of Head Office Location / 2024-07-11 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Business Performance Forecast (Consolidated) / 2025-04-08 Disclosures
  • [Disclosure] Hanwha Systems (272210) – Provisional Financial Results (Consolidated) / 2024-04-26 Disclosures
  • [Research] Samsung Electro-Mechanics (009150) – iM Securities | LTA · AI Server · Business Model Shift / 2026-05-04 RESEARCH

[Disclosure] HPSP (403870) – Submission of Audit Report / 2026-03-19

Posted on March 19, 2026August 1, 2026 By K-STOCK Editor

Fact Source: Financial Supervisory Service DART

💡 3-Second Summary

HPSP submitted its audit report, receiving an ‘Unqualified’ audit opinion from its external auditor for the FY2025 financial statements.

📊 Key Disclosure Contents & Summary Metrics

  • Disclosure Title: Submission of Audit Report
  • Auditor Information & Opinions:
    • External Auditor: Woori Accounting Corporation
    • Audit Opinion: Unqualified
    • Material Uncertainty Related to Going Concern: Not Applicable
    • Adverse Audit (Review) Opinion on Internal Accounting Control System: Not Applicable
    • Date of Audit Report Receipt: 2026-03-19
    • Subject to Consolidated Financial Statements: No (Separate Financial Statements Basis)
  • Key Financial Results (FY2025 Separate Basis):
    • Total Assets: KRW 369,707,189,477 (KRW 369.7B)
    • Total Liabilities: KRW 61,476,437,245 (KRW 61.5B)
    • Total Equity: KRW 308,230,752,232 (KRW 308.2B)
    • Capital Stock: KRW 41,805,284,000 (KRW 41.8B)
    • Revenue: KRW 172,964,572,189 (KRW 173.0B)
    • Operating Income: KRW 89,902,342,748 (KRW 89.9B)
    • Income Before Income Taxes: KRW 94,351,707,892 (KRW 94.4B)
    • Net Income: KRW 72,662,225,546 (KRW 72.7B)
  • Year-over-Year Comparison (FY2024 vs FY2025):
    • Revenue: KRW 181,401,607,828 → KRW 172,964,572,189 (Decrease)
    • Operating Income: KRW 93,945,693,775 → KRW 89,902,342,748 (Decrease)
    • Net Income: KRW 86,280,231,062 → KRW 72,662,225,546 (Decrease)
  • Other Key Notes:
    • Financial statements were prepared in accordance with K-IFRS.
    • The financial statements in this audit report are subject to final approval at the general meeting of shareholders and may be modified during the approval process.

📝 Editor’s Comment (Key Follow-up Checkpoint)

📌 Final Approval of Financial Statements at General Shareholders’ Meeting

This disclosure reports the submission of the audit report with an unqualified opinion from the external auditor. Because the figures presented remain subject to approval at the upcoming Annual General Meeting of Shareholders, verifying whether the financial statements are approved as submitted is important for confirming the finalized financial results. Related updates can be verified under the “Results of Annual General Meeting of Shareholders” filing or in the “Financial Statements” section of future periodic regulatory reports.

📢 Disclaimer & Source Notice

Source: This content was newly structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).

Investment Risk Warning: This content is provided solely for information purposes and language reference. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific securities. All investment decisions and financial responsibilities rest entirely with the individual investor.

Contact: For compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Semiconductors, Disclosures

Post navigation

Previous Post: [Disclosure] Hanwha Ocean (042660) – Decision on Paid-in Capital Increase / 2026-03-19
Next Post: [Disclosure] Hanwha Ocean (042660) – Decision on Paid-in Capital Increase (Major Management Matters of Subsidiary) / 2026-03-19

Related Posts

  • [Disclosure] SK hynix (000660 / SKHY) – Change in Revenue or Income Structure Exceeding 30% (15% for Large-Scale Corporations) / 2026-01-28 Semiconductors
  • [Disclosure] Samsung Biologics (207940) – (Correction) Single Sales and Supply Contract / 2025-11-13 Disclosures
  • [Disclosure] SK Square (402340) – Decision on Acquisition of Tangible Assets / 2026-03-24 Semiconductors
  • [Disclosure] Hanwha Aerospace (012450) – Trading Suspension and Lifting of Suspension / 2024-04-05 Disclosures
  • [Disclosure] Hyundai Motor (005380) – Reference Price for Interim (Quarterly) Ex-Dividend (Hyundai Motor 3PB) / 2025-05-28 Disclosures
  • [Disclosure] PSK Holdings (031980) – Setting of Record Date or Closure Period of Shareholder Register / 2023-12-15 Semiconductors
  • [Research] Samsung Electro-Mechanics (009150) – Mirae Asset Securities | AI6 Direct Beneficiary · FC-BGA TAM Expansion · MLCC Price Hike / 2026-03-05 RESEARCH
  • [Disclosure] ISU PETASYS(007660) – Investor Relations (IR) Holding Announcement / 2025-09-11 Semiconductors
  • [Disclosure] Samsung Biologics (207940) – Provisional Operating Results Based on Consolidated Financial Statements (Fair Disclosure) / 2024-10-23 Disclosures
  • [Disclosure] Celltrion (068270) – Approval of Phase 3 Clinical Trial Plan for CT-P13 SC (Zymfentra) in the U.S. (Rheumatoid Arthritis) / 2024-08-19 Disclosures
  • [Disclosure] Celltrion (068270) – Execution of Joint R&D and License Agreement for PD-1 x VEGF x IL-2v Tri-functional Fusion Protein / 2025-10-31 Disclosures
  • [Disclosure] Hanmi Semiconductor (042700) – Investor Relations (IR) Presentation / 2024-05-17 Semiconductors
  • [Disclosure] ALTEOGEN (196170) – Results of Annual General Meeting of Shareholders / 2026-03-31 Disclosures
  • [Disclosure] Hanwha Aerospace (012450) – (Correction) Acquisition of Shares in Other Corporation / 2025-01-08 Disclosures

Copyright © 2026 K-Stock Briefing.

Powered by PressBook News Dark theme